Why the study?
Does Withania coagulans fruit extract prevent cisplatin-induced nephrotoxicity in rats?
Does Withania coagulans fruit extract prevent cisplatin-induced nephrotoxicity in rats?
Withania coagulans fruit extract demonstrates dose-dependent protection against cisplatin-induced nephrotoxicity in a rat model via antioxidant and anti-inflammatory mechanisms.
Hypothesis-generating for renoprotection in cisplatin models; human trials needed before any clinical consideration.
BACKGROUND: ) reported to possess several bioactive compounds as curative agents for various clinical conditions. Cisplatin is a chemotherapeutic drug to treat sarcomas, carcinomas, lymphomas, cervical cancer, germ cell tumors, etc. The major factor that limits its clinical use is its dose-dependent nephrotoxicity. AIM: extract and its modulatory effects against cisplatin-induced nephrotoxicity and genotoxicity. MATERIALS AND METHODS: fruit extract at different doses had been evaluated. It includes quantification of serum kidney toxicity markers, renal tissue oxidative stress biomarkers and pro-inflammatory cytokines level, DNA fragmentation assay, and histopathological examination of renal tissue. RESULTS: possess dose dependent protective effect against cisplatin induced kidney damages, primarily through its free radical scavenging and anti inflammatory activity. SUMMARY: WHO: World Health Organization, SOD: Superoxide dismutase, CAT: Catalase, HPTLC: High-performance thin layer chromatography, p.o.: Per.oral, i.p.: Intraperitoneal, TNF-α: Tumor necrosis factor-alpha, IL-1β: Interleukin 1-beta, IL-6: Interleukin-6.
No takes yet. Share an insight, caveat, or question.
Hemalatha et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: